MXPA04000162A - Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. - Google Patents
Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.Info
- Publication number
- MXPA04000162A MXPA04000162A MXPA04000162A MXPA04000162A MXPA04000162A MX PA04000162 A MXPA04000162 A MX PA04000162A MX PA04000162 A MXPA04000162 A MX PA04000162A MX PA04000162 A MXPA04000162 A MX PA04000162A MX PA04000162 A MXPA04000162 A MX PA04000162A
- Authority
- MX
- Mexico
- Prior art keywords
- mammals
- increasing
- vivo efficacy
- inhibiting inflammation
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
Abstract
La presente invencion se refiere al uso de sustitutos de nucleotidos para incrementar la eficacia in vivo de moleculas de acido nucleico y tambien para inhibir la inflamacion en mamiferos. Mas particularmente, la presente invencion se refiere al uso de 2??6?? diaminopurina (DAP) y analogos del mismo per se, en composiciones anti-inflamatorias, y tambien a la preparacion de moleculas de acido nucleico que tienen una eficacia fisiologica in vivo incrementada y una toxicidad reducida tal como se compara con oligos convencionales. La presente invencion es particularmente util para la preparacion de oligonucleotidos antisentido para tratar enfermedades pulmonares/respiratorias tales como fibrosis quistica, asma, bronquitis cronica, enfermedad del pulmon de obstruccion cronica, bronquitis eosinofilica, alergias, rinitis alergica, fibrosis pulmonar, sindrome de distension respiratoria de adulto, sinusitis, virus sincitial respiratorio y otras infecciones virales del tracto respiratorio y cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30307101P | 2001-07-06 | 2001-07-06 | |
PCT/CA2002/001046 WO2003004511A2 (en) | 2001-07-06 | 2002-07-08 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04000162A true MXPA04000162A (es) | 2006-05-22 |
Family
ID=23170407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04000162A MXPA04000162A (es) | 2001-07-06 | 2002-07-08 | Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US7745420B2 (es) |
EP (1) | EP1406667B1 (es) |
JP (1) | JP4903984B2 (es) |
AT (1) | ATE386548T1 (es) |
AU (1) | AU2002319033B2 (es) |
CA (1) | CA2451738C (es) |
DE (1) | DE60225141T2 (es) |
DK (1) | DK1406667T3 (es) |
ES (1) | ES2301659T3 (es) |
MX (1) | MXPA04000162A (es) |
NZ (1) | NZ530360A (es) |
PT (1) | PT1406667E (es) |
WO (1) | WO2003004511A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2450929T3 (es) * | 2004-10-29 | 2014-03-25 | Topigen Pharmaceuticals Inc. | Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas |
AU2007282224B2 (en) | 2006-08-11 | 2013-08-29 | Vico Therapeutics B.V. | Methods and means for treating DNA repeat instability associated genetic disorders |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
AU2009246000B2 (en) * | 2008-05-15 | 2014-09-04 | Topigen Pharmaceuticals Inc. | Oligonucleotides for treating inflammation and neoplastic cell proliferation |
WO2010048731A1 (en) * | 2008-10-31 | 2010-05-06 | Christopher John Ong | Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents |
US9622909B2 (en) | 2009-02-26 | 2017-04-18 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
US9301871B2 (en) | 2009-02-26 | 2016-04-05 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
US8231664B2 (en) * | 2009-02-26 | 2012-07-31 | Advanced Cooling Therapy, Llc | Devices and methods for controlling patient temperature |
US9326890B2 (en) | 2009-02-26 | 2016-05-03 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
JP2014511181A (ja) * | 2011-02-24 | 2014-05-15 | ファーマキシス リミテッド | キメラ骨格および2−アミノ−2’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤 |
BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
US9272016B2 (en) * | 2012-04-20 | 2016-03-01 | University Of Iowa Research Foundation | Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells |
CN104271741A (zh) * | 2012-04-23 | 2015-01-07 | 普罗森萨科技有限公司 | 用于治疗神经肌肉障碍的具有改善特性的rna调节寡核苷酸 |
FR3057774A1 (fr) * | 2016-10-21 | 2018-04-27 | Museum National D'histoire Naturelle | Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3337530A (en) * | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
JPH01173818A (ja) * | 1987-12-28 | 1989-07-10 | Aisin Aw Co Ltd | 車両用ナビゲーション装置 |
US5523205A (en) * | 1988-08-02 | 1996-06-04 | Institut Pasteur | DNA probes specific for hemolytic listeria |
US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
CA2102224A1 (en) * | 1991-04-19 | 1992-10-20 | Toshio Kitamura | Human interleukin-3-receptor component |
US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
AU4595399A (en) * | 1998-06-19 | 2000-01-10 | Mcgill University | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
EP1102786A4 (en) * | 1998-08-03 | 2002-03-06 | Univ East Carolina | AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS |
US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
BR0006019A (pt) | 1999-04-06 | 2001-03-13 | Univ East Carolina | Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante |
-
2002
- 2002-07-08 DK DK02748499T patent/DK1406667T3/da active
- 2002-07-08 JP JP2003510677A patent/JP4903984B2/ja not_active Expired - Fee Related
- 2002-07-08 CA CA2451738A patent/CA2451738C/en not_active Expired - Fee Related
- 2002-07-08 NZ NZ530360A patent/NZ530360A/en not_active IP Right Cessation
- 2002-07-08 EP EP02748499A patent/EP1406667B1/en not_active Expired - Lifetime
- 2002-07-08 ES ES02748499T patent/ES2301659T3/es not_active Expired - Lifetime
- 2002-07-08 AT AT02748499T patent/ATE386548T1/de active
- 2002-07-08 US US10/482,949 patent/US7745420B2/en not_active Expired - Fee Related
- 2002-07-08 DE DE60225141T patent/DE60225141T2/de not_active Expired - Lifetime
- 2002-07-08 WO PCT/CA2002/001046 patent/WO2003004511A2/en active IP Right Grant
- 2002-07-08 PT PT02748499T patent/PT1406667E/pt unknown
- 2002-07-08 MX MXPA04000162A patent/MXPA04000162A/es active IP Right Grant
- 2002-07-08 AU AU2002319033A patent/AU2002319033B2/en not_active Ceased
-
2009
- 2009-05-06 US US12/436,493 patent/US20100286235A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100286235A1 (en) | 2010-11-11 |
NZ530360A (en) | 2006-01-27 |
US7745420B2 (en) | 2010-06-29 |
WO2003004511A3 (en) | 2003-07-10 |
DK1406667T3 (da) | 2008-06-16 |
CA2451738A1 (en) | 2003-01-16 |
US20050032723A1 (en) | 2005-02-10 |
DE60225141T2 (de) | 2009-03-05 |
ES2301659T3 (es) | 2008-07-01 |
EP1406667A2 (en) | 2004-04-14 |
CA2451738C (en) | 2013-09-17 |
PT1406667E (pt) | 2008-05-23 |
EP1406667B1 (en) | 2008-02-20 |
DE60225141D1 (de) | 2008-04-03 |
AU2002319033B2 (en) | 2008-01-10 |
JP2004532900A (ja) | 2004-10-28 |
JP4903984B2 (ja) | 2012-03-28 |
WO2003004511A2 (en) | 2003-01-16 |
ATE386548T1 (de) | 2008-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04000162A (es) | Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. | |
JP2008535859A (ja) | 感染症によって悪化した喘息を治療するための方法 | |
JP6434204B2 (ja) | オリゴヌクレオチドの処方に関する組成物および方法 | |
ES2217569T3 (es) | Sales de di(uridina 5'-tetrafosfato), metodo para su preparacion y usos de las mismas. | |
SG146649A1 (en) | Mucoactive agents for treating a pulmonary disease | |
EA012573B1 (ru) | РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
DK0981534T3 (da) | Dinukleotider og deres anvendelser | |
JP2011500003A5 (es) | ||
SE0200356D0 (sv) | Novel use | |
CN102099474B (zh) | 用于治疗炎症和赘生性细胞增殖的寡核苷酸 | |
JP2017512502A (ja) | 新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
JP2008516991A5 (es) | ||
US6765090B2 (en) | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | |
US6548658B2 (en) | Di-(uridine 5′)-tetraphosphate and salts thereof | |
AU2012220299A1 (en) | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |